WO2008091681A3 - Theramutein modulators - Google Patents

Theramutein modulators Download PDF

Info

Publication number
WO2008091681A3
WO2008091681A3 PCT/US2008/000960 US2008000960W WO2008091681A3 WO 2008091681 A3 WO2008091681 A3 WO 2008091681A3 US 2008000960 W US2008000960 W US 2008000960W WO 2008091681 A3 WO2008091681 A3 WO 2008091681A3
Authority
WO
WIPO (PCT)
Prior art keywords
variants
activators
inhibitors
endogenous protein
endogenous
Prior art date
Application number
PCT/US2008/000960
Other languages
French (fr)
Other versions
WO2008091681A2 (en
Inventor
Gerard M Housey
Original Assignee
Gerard M Housey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gerard M Housey filed Critical Gerard M Housey
Publication of WO2008091681A2 publication Critical patent/WO2008091681A2/en
Publication of WO2008091681A3 publication Critical patent/WO2008091681A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Abstract

This invention relates to agents that are inhibitors or activators of variant forms of endogenous proteins and novel methods of identifying such variants. Of particular interest are inhibitors and activators of endogenous protein variants, encoded by genes which have mutated, which variants often arise or are at least first identified as having arisen following exposure to a chemical agent which is known to be an inhibitor or activator of the corresponding unmutated endogenous protein.
PCT/US2008/000960 2007-01-23 2008-01-23 Theramutein modulators WO2008091681A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89728207P 2007-01-23 2007-01-23
US60/897,282 2007-01-23

Publications (2)

Publication Number Publication Date
WO2008091681A2 WO2008091681A2 (en) 2008-07-31
WO2008091681A3 true WO2008091681A3 (en) 2008-09-25

Family

ID=39645081

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/000960 WO2008091681A2 (en) 2007-01-23 2008-01-23 Theramutein modulators

Country Status (1)

Country Link
WO (1) WO2008091681A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102060782A (en) * 2010-11-18 2011-05-18 孙智华 Method for preparing chloropyrimidines or analogues thereof
GB201300435D0 (en) 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
WO2014165788A1 (en) 2013-04-05 2014-10-09 The Procter & Gamble Company Personal care composition comprising a pre-emulsified formulation
US10806688B2 (en) 2014-10-03 2020-10-20 The Procter And Gamble Company Method of achieving improved volume and combability using an anti-dandruff personal care composition comprising a pre-emulsified formulation
US9993404B2 (en) 2015-01-15 2018-06-12 The Procter & Gamble Company Translucent hair conditioning composition
CA2977961A1 (en) 2015-02-25 2016-09-01 The Procter & Gamble Company Fibrous structures comprising a surface softening composition
WO2016196514A1 (en) * 2015-06-01 2016-12-08 Regents Of The University Of Minnesota Thiourea catalysts
MX2018000351A (en) 2015-07-10 2018-11-12 Procter & Gamble Fabric care composition comprising metathesized unsaturated polyol esters.
JP6970094B2 (en) 2016-01-20 2021-11-24 ザ プロクター アンド ギャンブル カンパニーThe Procter & Gamble Company Hair conditioning composition containing monoalkyl glyceryl ether
DK3436434T3 (en) 2016-03-31 2020-09-21 Oncternal Therapeutics Inc INDOLIN ANALOGS AND USES THEREOF
US10894932B2 (en) 2016-08-18 2021-01-19 The Procter & Gamble Company Fabric care composition comprising glyceride copolymers
JOP20190024A1 (en) 2016-08-26 2019-02-19 Gilead Sciences Inc Substituted pyrrolizine compounds and uses thereof
PL3759109T3 (en) 2018-02-26 2024-03-04 Gilead Sciences, Inc. Substituted pyrrolizine compounds as hbv replication inhibitors
WO2022115645A1 (en) 2020-11-25 2022-06-02 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115992A1 (en) * 2004-05-23 2005-12-08 Housey Pharmaceuticals, Inc. Theramutein modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005115992A1 (en) * 2004-05-23 2005-12-08 Housey Pharmaceuticals, Inc. Theramutein modulators

Also Published As

Publication number Publication date
WO2008091681A2 (en) 2008-07-31

Similar Documents

Publication Publication Date Title
WO2008091681A3 (en) Theramutein modulators
WO2007037898A3 (en) Theramutein modulators
EP2447252A3 (en) Theramutein modulators
WO2009053484A3 (en) Electron deficient olefins and curable compositions prepared therefrom
WO2011106770A3 (en) Modified proteins and methods of making and using same
MX2010010209A (en) Substituted 4-hydroxypyrimidine-5-carboxamides.
EA201001860A1 (en) DPP-4 inhibitors for the treatment of non-alcoholic fatty liver
WO2007136834A3 (en) Combined extension and ligation for nucleic acid assembly
AU2009236219A8 (en) Silencing of CSN5 gene expression using interfering RNA
WO2007016591A3 (en) Compositions and methods for monitoring and altering protein folding and solubility
WO2009037473A3 (en) Nucleobase characterisation
WO2009039189A3 (en) Compositions comprising stat3 sirna and methods of use thereof
WO2008157697A3 (en) Copolymer assay
WO2009002440A3 (en) Compositions comprising human egfr-sirna and methods of use
MX2009012170A (en) Weak acid based concrete stain.
WO2008118626A3 (en) Inhibitors of jnk and methods for identifying inhibitors of jnk
WO2010053573A3 (en) Screen for inhibitors of filovirus and uses therefor
WO2006081462A3 (en) Multi-component inhibitors of nucleic acid polymerases
TW200621744A (en) Mercaptoamides as histone deacetylase inhibitors
WO2011100752A3 (en) Methods and materials for assessing rna expression
ATE507250T1 (en) SAMPLE LYSIS AND COATING OF A REACTION SURFACE
WO2010000851A3 (en) Methods for modulating angiogenesis via dystrophin dp71
MX2007011411A (en) Rage/diaphanous interaction and related compositions and methods.
TW200801015A (en) Substituted aminophenylsulfonamide compounds as HIV protease inhibitor
WO2010042685A3 (en) Inhibitors of the atb(0,+) transporter and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08713273

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08713273

Country of ref document: EP

Kind code of ref document: A2